{"entity":{"id":"nct05680922","kind":"trial","name":"DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 1 trial of LB2102 in extensive-stage small-cell lung cancer and large cell neuroendocrine carcinoma of the lung, run by Legend Biotech USA Inc, active but no longer recruiting.","summary":"DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05680922 by Legend Biotech USA Inc; 41 participants are planned, it started on 2023-07-26; the registry gives 2027-12 as its primary completion date. Interventions recorded: LB2102. Conditions listed: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05680922","url":"https://clinicaltrials.gov/study/NCT05680922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["lb2102"],"companies":["legend-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05680922","phase":"1","setting":"A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","sponsor":"Legend Biotech USA Inc","started":"2023-07-26","enrolled":41,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05680922/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"lb2102","kind":"drug","name":"LB2102","route":"/drugs/lb2102/"}],"company":[{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/"}]}}